Patricia Chavarria
Family · South Miami, FLNPI 1922163112
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Medtronic at 56.7% of the total. Reporting peaked in 2023 at $1,478 and has fallen 52.5% since, to $702 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Pfizer$258
- Johnson & Johnson$256
- Boston Scientific$241
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$151
- Novartis$127
- plus $1K from 20 others
What the payments were for
- Consulting fees$2806%
- Food & beverage$4,54994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,829 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 178 | $207,033 |
| XareltoRivaroxaban | 39 | $39,362 |
| EntrestoSacubitril/Valsartan | 26 | $29,992 |
| Metoprolol Succinate | 111 | $1,258 |
| Flecainide Acetate | 22 | $992 |
| Bumetanide | 12 | $710 |
| Amiodarone Hcl | 41 | $614 |
| Hydralazine Hcl | 13 | $388 |
| Losartan Potassium | 28 | $335 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $320 |
| Nifedipine ErNifedipine | 22 | $243 |
| Amlodipine Besylate | 35 | $231 |
| Atorvastatin Calcium | 12 | $90 |
| Metoprolol Tartrate | 12 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $258 | $207,033178 claims |
| Johnson & JohnsonXarelto | $256 | $39,36239 claims |
| NovartisEntresto | $127 | $29,99226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in South Miami
- Darlena BanasSouth Miami$64K
- Naime Reyno RamosSouth Miami$44K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.